Login to Your Account



HGSI Ponders Next Move After Rebuffing GSK's $2.6B Offer

By Marie Powers
Staff Writer

Friday, April 20, 2012
As analysts weighed in on the unsolicited offer by GlaxoSmithKline plc (GSK) to purchase Human Genome Sciences Inc. (HGSI) for $13 per share in cash, or $2.6 billion, shares (NASDAQ:HGSI) of the biotech reached $14.61 before closing at $14.17 for a gain of 97.6 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription